Table 2

Endpoints

SPEED study (N=87)Pivotal trial (N=125)
Revascularization (TIMI 2–3) (%)90.881.6
 TIMI 2 (%)60.954.4
 TIMI 3 (%)29.9 (N=86)27.2
Procedural SAEs (%)3.52.4
Symptomatic ICH (%)1411
All-cause deaths (%)25.632.8
90-day mRS ≤ 2 (%)34.9 (N=63)25.0
  • ICH, intracranial hemorrhage; mRS, modified Rankin scores; TIMI, Thrombolysis In Myocardial Infarction; SAE, serious adverse event.